News
FBRX
76.92
+0.04%
0.03
Forte Biosciences’ FB102 Trial Moves Forward: What Investors Should Watch
TipRanks · 4d ago
Weekly Report: what happened at FBRX last week (0810-0814)?
Weekly Report · 6d ago
Alger Small Cap Growth Fund Q2 2026 Portfolio Review
Seeking Alpha · 08/14 09:00
Execution Risks Threaten Forte Biosciences–argenx Merger and Shareholder Value
TipRanks · 08/14 06:01
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Forte Biosciences (FBRX) and Demant (OtherWILLF)
TipRanks · 08/13 07:20
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Barchart · 08/11 10:56
Weekly Report: what happened at FBRX last week (0803-0807)?
Weekly Report · 08/10 10:25
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
Barchart · 08/08 08:54
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Seeking Alpha · 08/06 12:13
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte Biosciences
Benzinga · 08/06 11:59
Weekly Report: what happened at FBRX last week (0727-0731)?
Weekly Report · 08/03 10:25
Key deals this week: Ambarella, MarketAxess, argenx SE, TransDigm, and more
Seeking Alpha · 08/02 13:15
Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals
NASDAQ · 07/31 14:51
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement
Barchart · 07/30 09:15
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Barchart · 07/28 13:15
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
TipRanks · 07/28 12:01
Argenx price target raised to $1,050 from $1,000 at Wedbush
TipRanks · 07/28 12:00
Forte Biosciences Cut to Equal-Weight From Overweight by Barclays
Dow Jones · 07/28 11:02
Forte Biosciences Price Target Raised to $77.00/Share From $74.00 by Barclays
Dow Jones · 07/28 11:02
Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77
Benzinga · 07/28 10:52
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.